Specifically, Boston leads the way in embracing new research models (for example, Research at the Broad Institute of Harvard and MIT) and, in building a new research culture that has strong roots in academia and the pharma sector. A recent contribution of US$650 million as the philanthropic donation to Broad is the true testimony. It […]
The historical approach to clinical drug development, and one that served drug companies well for the past thirty years, was to initiate testing in humans at clinical research units, typically located in the UK and the US and to proceed further to Phase II testing and beyond to patients with clinical evidence of the disease […]
The ideal goal of cancer vaccine is to elicit potent anti-tumour immune responses without any contributing side-effects. The major aim is to stimulate both innate and adaptive immunity that can recognise and subsequently eliminate the tumours mass. Cancer immunotherapy continues to be a field of intense research, especially the induction of active immunity. The existence […]
The pharmaceutical industry now operates in a complex and dynamic global environment. The pace of change is much faster and far less predictable than ever before. To survive and prosper in today’s business environment we need to urgently rethink about how we operate. Specifically, we must challenge the thinking that created our current state and […]
Many of the blockbuster biological products that currently dominate the markets are coming to the end of their patent protection. The opportunity to provide more affordable “generic” versions is now attracting the interest of both generic and research-based pharmaceutical companies. The development of “generic” biological medicines referred to as “biosimilars” in Europe and increasingly in […]
Organismic assays are better and more predictive for testing putative therapeutics than molecular assays, but it is difficult and expensive to work with animals, and the relevance of these assays’ results in humans is often low. Human cell-based assays-which are less complicated than many organismic assays-are an attractive option for drug screening because cells are […]
The advent of modern drug discovery techniques such as quantitative structure-activity relationships, combinatorial and high-throughput chemistry has contributed to this quest. The Lipinski Rule of 5 and variants thereof, acknowledge that potential drug molecules tend to be more lipophilic with logP values up to 5 and sometimes higher. Water solubility-enhancing formulation strategies have therefore become […]
Ion channels have been excellent drug discovery targets for decades with clinically meaningful drugs identified targeting sodium channels, including (e.g. lamotrigine), calcium channels (e.g. amlopdipine), GABA receptors (e.g. diazepam) and ATP-gated potassium channels (e.g. glipizide) and several others. However, new ion channel modulators have not been emerging at a rapid pace in the recent years, […]
Really Informative article from Mr.
Arab Drug Industry is dominating but need to concentrate on (...)
China is leading the world in R&D as they have low-cost (...)
I really like the article and the way it was editing... The (...)
I really like the article and the way it was edited... The (...)
